


DISCOVERY 1TO3

Feature

- DISCOVERY 1TO3 demonstrated rapid strut coverage of Ultimaster DES, with the majority of strut coverage process taking place within the first month after stent implantation.
- The unique sequential OFDI analysis at 1, 2 and 3 months of treated lesions improves our insight into the embedding of novel metallic BP-DES.


85.1%

endothelial coverage even at 1 month




Clinical outcomes

Frequency of strut coverage of combined both single and overlapped stents at 1,2 and 3 months.



Study design



Study device



Abluminal gradient coating can facilitate endothelial coverage and reduce drug/polymer dose.

Patient background comparison with historical control

Baseline Patient Characteristics	n=60 Patients*
Age, y (mean±SD)	67.2±9.9
Sex, males (%)	73.3
Diabetes mellitus (%)	23.3
Hypertension (%)	63.3
Dyslipidemia (%)	67.8
Family history of CAD (%)	30.0
Current smoker (%)	13.6
Previous PCI (%)	26.7
Previous CABG (%)	3.3
Previous MI (%)	21.7

Angina status (%)	
Stable patients	56.7
ACS	36.7
Moderate renal insufficiency GFR or MDRD=45-60, (%)	20.0

Baseline lesion characteristics*	
Vessels diseased	2.2 ± 0.5
Lesions detected	3.2 ± 1.6
Lesions treated-baseline	1.4 ± 0.6
Lesions treated-staged procedure at 1 mo (37 patients)	1.1 ± 0.4
Total lesions treated	2.1 ± 0.7
Stents implanted per lesion	1.2 ± 0.4
Implanted stent length per lesion, mm	22.0 ± 10.9
Implanted stent length per patient, mm	50.4 ± 21.4

Reference

Bernard Chevalier, Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging, Circulation Cardiovascular Interventions, Dec 2017, Vol 10, Issue 12.



[Publication >](#)

Contact

Link to contact page



Detailed specification



Clinical evidence



Support

